PortfoliosLab logoPortfoliosLab logo

Documentation

Upgrade your plan
CANC vs. IHE
Performance
Return for Risk
Drawdowns
Volatility
Dividends

CANC vs. IHE

Last updated Jun 4, 2026

CANC (Tema Oncology ETF) and IHE (iShares U.S. Pharmaceuticals ETF) are both Health & Biotech Equities funds. CANC is actively managed, while IHE is passively managed. Over the past 3 years, CANC returned 107.76%/yr vs 17.47%/yr for IHE. At a 0.41 correlation, their price movements are largely independent. CANC charges 0.75%/yr vs 0.42%/yr for IHE.

Performance

CANC vs. IHE - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Tema Oncology ETF (CANC) and iShares U.S. Pharmaceuticals ETF (IHE). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, CANC achieves a 4.82% return, which is significantly lower than IHE's 6.47% return.

CANC

1D
0.08%
1M
-3.73%
YTD
4.82%
6M
3.86%
1Y
47.37%
3Y*
107.76%
5Y*
—
10Y*
—

IHE

1D
1.16%
1M
1.80%
YTD
6.47%
6M
8.51%
1Y
40.15%
3Y*
17.47%
5Y*
9.98%
10Y*
7.81%
*Multi-year figures are annualized to reflect compound growth (CAGR)

CANC vs. IHE - Yearly Performance Comparison

2026 (YTD)20252024202320222021
CANC
Tema Oncology ETF		4.82%42.92%-5.37%510.51%-85.34%-51.82%
IHE
iShares U.S. Pharmaceuticals ETF		6.47%31.69%8.13%1.06%-4.87%9.46%

Correlation

The correlation between CANC and IHE is 0.75, which is moderate. They share some common price drivers but move independently often enough to provide real diversification benefit when combined.

Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.75

Correlation (3Y)
Calculated over the trailing 3-year period

0.63

Correlation (All Time)
Calculated using the full available price history since Oct 1, 2021

0.41

Over the past year, CANC and IHE have become more correlated (0.75) than their long-term average of 0.41, meaning their price movements have been converging.

CANC vs. IHE - Sectors Allocation Comparison

Sectors
CANC
IHE

Healthcare

100.0%
100.0%

Basic Materials

-

-

Communication Services

-

-

Consumer Cyclical

-

-

Consumer Defensive

-

-

Energy

-

-

Financial Services

-

-

Industrials

-

-

Real Estate

-

-

Technology

-

-

Utilities

-

-

Healthcare

CANC
100.0%
IHE
100.0%

Basic Materials

CANC

-

IHE

-

Communication Services

CANC

-

IHE

-

Consumer Cyclical

CANC

-

IHE

-

Consumer Defensive

CANC

-

IHE

-

Energy

CANC

-

IHE

-

Financial Services

CANC

-

IHE

-

Industrials

CANC

-

IHE

-

Real Estate

CANC

-

IHE

-

Technology

CANC

-

IHE

-

Utilities

CANC

-

IHE

-

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Tema Oncology ETF

iShares U.S. Pharmaceuticals ETF

Often compared with CANC:
CANC vs. IYHCANC vs. VOOCANC vs. JNJCANC vs. LLYCANC vs. VHTCANC vs. BBOTCANC vs. CGON
Often compared with IHE:
IHE vs. PPHIHE vs. XPHIHE vs. XLVIHE vs. VYMIHE vs. PJPIHE vs. IAKIHE vs. BBP

Return for Risk

CANC vs. IHE — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.
CANC
CANC Risk / Return Rank: 6969
Overall Rank
CANC Sharpe Ratio Rank: 6161
Sharpe Ratio Rank
CANC Sortino Ratio Rank: 6464
Sortino Ratio Rank
CANC Omega Ratio Rank: 5454
Omega Ratio Rank
CANC Calmar Ratio Rank: 9090
Calmar Ratio Rank
CANC Martin Ratio Rank: 7777
Martin Ratio Rank
IHE
IHE Risk / Return Rank: 7474
Overall Rank
IHE Sharpe Ratio Rank: 7171
Sharpe Ratio Rank
IHE Sortino Ratio Rank: 7575
Sortino Ratio Rank
IHE Omega Ratio Rank: 6565
Omega Ratio Rank
IHE Calmar Ratio Rank: 8585
Calmar Ratio Rank
IHE Martin Ratio Rank: 7575
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

CANC vs. IHE - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Tema Oncology ETF (CANC) and iShares U.S. Pharmaceuticals ETF (IHE). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

CANCIHEDifference
Sharpe ratioReturn per unit of total volatility
2.06
2.36

-0.30

Sortino ratioReturn per unit of downside risk
2.96
3.43

-0.47

Omega ratioGain probability vs. loss probability

1.34

1.40

-0.07

Calmar ratioReturn relative to maximum drawdown

5.49

4.76

+0.73

Martin ratioReturn relative to average drawdown

14.62

14.35

+0.27

Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

CANC vs. IHE - Sharpe Ratio Comparison

The current CANC Sharpe Ratio is 2.06, which is comparable to the IHE Sharpe Ratio of 2.36. The chart below compares the historical Sharpe Ratios of CANC and IHE, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Loading charts...

Sharpe Ratios by Period

CANCIHEDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

2.06

2.36

-0.30

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

—

0.62

—

Sharpe Ratio (10Y)

Calculated over the trailing 10-year period

—

0.43

—

Sharpe Ratio (All Time)

Calculated using the full available price history

-0.04

0.51

-0.54

Drawdowns

CANC vs. IHE - Drawdown Comparison

The maximum CANC drawdown since its inception was -97.53%, which is greater than IHE's maximum drawdown of -38.20%. Use the drawdown chart below to compare losses from any high point for CANC and IHE.

Loading charts...

Drawdown Indicators

CANCIHEDifference

Max Drawdown

Largest peak-to-trough decline

-97.53%

-38.20%

-59.33%

Max Drawdown (1Y)

Largest decline over 1 year

-8.67%

-8.47%

-0.20%

Max Drawdown (3Y)

Largest decline over 3 years

-30.27%

-15.92%

-14.35%

Max Drawdown (5Y)

Largest decline over 5 years

—

-16.03%

—

Max Drawdown (10Y)

Largest decline over 10 years

—

-29.59%

—

Current Drawdown

Current decline from peak

-56.55%

-2.80%

-53.75%

Average Drawdown

Average peak-to-trough decline

-73.19%

-7.92%

-65.27%

Ulcer Index

Depth and duration of drawdowns from previous peaks

3.25%

2.81%

+0.44%

Volatility

CANC vs. IHE - Volatility Comparison

Tema Oncology ETF (CANC) has a higher volatility of 6.26% compared to iShares U.S. Pharmaceuticals ETF (IHE) at 5.53%. This indicates that CANC's price experiences larger fluctuations and is considered to be riskier than IHE based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Loading charts...

Volatility by Period

CANCIHEDifference

Volatility (1M)

Calculated over the trailing 1-month period

6.26%

5.53%

+0.73%

Volatility (6M)

Calculated over the trailing 6-month period

16.69%

12.48%

+4.21%

Volatility (1Y)

Calculated over the trailing 1-year period

23.11%

17.07%

+6.04%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

280.27%

16.24%

+264.03%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

280.27%

18.05%

+262.22%

CANC vs. IHE - Expense Ratio Comparison

CANC has a 0.75% expense ratio, which is higher than IHE's 0.42% expense ratio.

Dividends

CANC vs. IHE - Dividend Comparison

CANC's dividend yield for the trailing twelve months is around 0.05%, less than IHE's 1.65% yield.

PositionTTM20252024202320222021202020192018201720162015
CANC
Tema Oncology ETF		0.05%0.06%3.00%0.56%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
IHE
iShares U.S. Pharmaceuticals ETF		1.65%1.76%1.73%1.39%2.01%1.49%1.19%1.40%1.25%1.36%0.92%1.93%

Frequently Asked Questions

CANC and IHE have a correlation of 0.75, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

CANC has higher volatility (6.26%) compared to IHE (5.53%). In terms of maximum drawdown, CANC dropped -97.53% vs IHE's -38.20%.

On 3-year performance, CANC leads with 107.76% vs 17.47% for IHE. On fees, IHE is cheaper at 0.42% per year. On volatility, IHE has been the lower-risk option at 5.53%. The better choice depends on whether you care most about return, fees, risk, or income.

Over the 3-year period, CANC has performed better with a 107.76% return vs 17.47%. Past performance does not guarantee future results, so compare this with risk, fees, and fund exposure.

IHE is cheaper with a 0.42% expense ratio, compared with 0.75% for CANC.

IHE has the higher dividend yield at 1.65%, compared with 0.05% for CANC.

They also come from different issuers: Tema and iShares. Their fees differ too: 0.75% for CANC and 0.42% for IHE.

IHE currently has the higher Sharpe Ratio (2.36 vs 2.06), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for CANC and IHE

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer